MAPT and Alzheimer disease: PP2A expression and activity were reduced in the post mortem brains of AD patients,16, 17, 18, 19 and genetically or pharmacologically reducing PP2A activity alone is sufficient to elicit tau histopathology and cognitive deficits in animal models.20, 21, 22, 23, 24, 25, 26